We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current RSPI market cap is 471.74k. The company's latest EPS is USD -0.0084 and P/E is 0.00.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -2.18M | -1.74M | -3.32M | -2.56M | -1.58M |
| Net Income | -2.59M | -2.12M | -5.74M | -3.52M | -3.97M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 124k | 45k | 85k | 209k | 23k |
| Total Liabilities | 5.86M | 7.49M | 8.15M | 10.22M | 11.9M |
| Total Equity | -5.73M | -7.45M | -8.06M | -10.01M | -11.88M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -428k | -487k | -513k | -956k | -144k |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | 376k | 471k | 497k | 956k | 143k |
| Market Cap | 471.74k |
| Price to Earnings Ratio | 0.00 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 471.74M |
| Average Volume (1 week) | 528.05k |
| Average Volume (1 Month) | 413.48k |
| 52 Week Change | -41.18% |
| 52 Week High | 0.0069 |
| 52 Week Low | 0.0002 |
| Spread (Intraday) | 0 (0%) |
| Company Name | RespireRx Pharmaceuticals Inc (CE) |
| Address |
900 foulk road wilmington, delaware 19803 |
| Website | https://www.respirerx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
